bioAffinity Technologies, Inc. (BIAF)
Oxford Ledge is still expanding full research coverage of BIAF. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
The company develops noninvasive lung cancer diagnostic tests using flow cytometry and machine learning, with additional development in lung disease and cancer therapeutics.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-07-07
- 8-K Other material event; Financial statements and exhibits 2026-06-30
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-06-18
- S-1/A Amended registration statement 2026-06-16
- 8-K Other material event; Financial statements and exhibits 2026-06-16
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for BIAF. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open BIAF in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.